Stockscreener 앱 받기
1.83
3.17%
-0.06
시간 외 거래:
1.81
-0.02
-1.09%
전일 마감가:
$1.89
열려 있는:
$1.89
하루 거래량:
110.35K
Relative Volume:
0.91
시가총액:
$268.62M
수익:
-
순이익/손실:
-
주가수익비율:
-8.1442
EPS:
-0.2247
순현금흐름:
-
1주 성능:
-10.29%
1개월 성능:
-1.61%
6개월 성능:
+7.02%
1년 성능:
+0.55%
1일 변동 폭
$1.80
$1.8945
1주일 범위
$1.80
$2.08
52주 변동 폭
$1.32
$2.71
Immutep Limited Adr Stock (IMMP) Company Profile
IMMP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
1.83 | 278.19M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-17 | 개시 | CapitalOne | Overweight |
| 2023-08-03 | 개시 | Robert W. Baird | Outperform |
| 2021-08-03 | 개시 | Ladenburg Thalmann | Buy |
| 2021-07-16 | 재개 | Maxim Group | Buy |
| 2018-09-28 | 개시 | B. Riley FBR | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
모두보기
Immutep Limited Adr 주식(IMMP)의 최신 뉴스
[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC FilingForm 6-K - Stock Titan
Immutep Limited Announces 2025 AGM with Key Resolutions - MSN
IMMP 20-F highlights: pipeline progress, IFRS results, Nasdaq ADSs - Stock Titan
Immutep reports Phase II neoadjuvant efti success in sarcoma via 6-K - Stock Titan
Immutep Completes FDA Project Optimus, Advances Cancer Immunotherapy - MSN
Immutep files 6-K with exhibit on FDA Project Optimus completion - Stock Titan
Immutep Announces Successful Completion of FDA Project Optimus Requirements - The Manila Times
Is Immutep Limited Depositary Receipt stock ready for a breakoutPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Reversal indicators forming on Immutep Limited Depositary Receipt stockMarket Activity Summary & Safe Entry Point Alerts - newser.com
What momentum shifts mean for Immutep Limited Depositary Receipt2025 Bull vs Bear & AI Forecasted Stock Moves - newser.com
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 - GlobeNewswire Inc.
Immutep Limited Depositary Receipt Stock Lags Behind Sector BenchmarksMarket Performance Report & Weekly Setup with High ROI Potential - beatles.ru
Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa - Yahoo Finance
12 Best Australian Stocks to Buy Right Now - Insider Monkey
Immutep Gains FDA Support for Cancer Therapy Development - TipRanks
Is Immutep Limited Depositary Receipt a good long term investmentFree Stock Market Return Analysis - PrintWeekIndia
Immutep Limited Depositary Receipt Stock Analysis and ForecastExceptional gains - jammulinksnews.com
Millennium Management LLC Sells 19,242 Shares of Immutep Limited (NASDAQ:IMMP) - Defense World
Jane Street Group LLC Has $98,000 Position in Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep Ltd Highlights Immune System Innovations at Healthcare Conference - TipRanks
Market Highlights: Immutep Limited ADR (IMMP) Ends on a Low Note at 1.93 - DWinneX
Immutep stock soars on promising trial results By Investing.com - Investing.com Australia
Immutep stock soars on promising trial results - Investing.com
Immutep Quarterly Activities Report Q3 FY25 - The Manila Times
Immutep Advances Cancer Trials with Promising Developments - TipRanks
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now? - AInvest
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewswire
Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com
Immutep appoints research institute to conduct first-in-human study of IMP761 - Biotech Dispatch
symbol__ Stock Quote Price and Forecast - CNN
Immutep LimitedADR (IMMP) Price Target Increased by 5.10% to 2.59 - Nasdaq
Immutep Announces Successful Meeting with the FDA on - GlobeNewswire
Immutep Announces GMP Manufacturing Process Developed for - GlobeNewswire
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - FinancialContent
FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - targetedonc.com
72 Biggest Movers From Friday - Benzinga
Immutep Limited Share Price ADR each Representing 10 Shares - Hargreaves Lansdown
Immutep valuation increased 16% to $510 million by Edison Investment Research - Proactive financial news
IMM Stock Price and Chart — ASX:IMM - TradingView
Prima BioMed (IMMP) Stock Price, News & Analysis - MarketBeat
IMMP Stock Price and Chart — NASDAQ:IMMP - TradingView
Prima BioMed Share Price | NASDAQ IMMP Stock - Investing.com Australia
Prima BioMed Stock Price Today | NASDAQ: IMMP Live - Investing.com
Immutep Ltd Share Price | ASX IMM Stock - Investing.com Australia
Immutep Limited Adr (IMMP) 재무 분석
Immutep Limited Adr (IMMP)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.64%
0.35%
자본화:
|
볼륨(24시간):